Literature DB >> 29599518

Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history.

Bettina Meiser1, Veronica F Quinn2, Gillian Mitchell3,4, Kathy Tucker5, Kaaren J Watts2, Belinda Rahman2, Michelle Peate2,6, Christobel Saunders7, Elizabeth Geelhoed8, Margaret Gleeson9, Kristine Barlow-Stewart10, Michael Field11, Marion Harris12, Yoland C Antill13, Rachel Susman14, Michael T Bowen15,16, Llew Mills2, Judy Kirk17,18.   

Abstract

In patients with early breast cancer, personal and tumour characteristics other than family history are increasingly used to prompt genetic testing to guide women's cancer management (treatment-focused genetic testing, 'TFGT'). Women without a known strong family history of breast and/or ovarian may be more vulnerable to psychological sequelae arising from TFGT. We compared the impact of TFGT in women with (FH+) and without (FH-) a strong family history on psychological adjustment and surgical decisions. Women aged <50 years with high-risk features were offered TFGT before definitive breast cancer surgery and completed self-report questionnaires at four time points over 12 months. All 128 women opted for TFGT. TFGT identified 18 carriers of a disease-causing variant (50.0% FH+) and 110 non-carriers (59.1% FH+). There were no differences based on family history in bilateral mastectomy (BM) uptake, p = .190, or uptake of risk-reducing bilateral salpingo-oophorectomy (RRBSO), p = .093. FH- women had lower decreases in anxiety a year after diagnosis, p = .011, and regret regarding their decision whether to undergo BM, p = .022, or RRBSO, p = .016 than FH + women. FH- carriers reported significantly higher regret regarding their TFGT choice (p = .024) and test-related distress (p = .012) than FH + carriers, but this regret/distress could not be attributed to a concern regarding a possible worse prognosis. These findings indicate that FH- women may require additional counselling to facilitate informed decisions. Carriers without a family history may require additional follow-up counselling to facilitate psychological adjustment to their positive variant results, extra support in making surgical decisions, and counselling about how best to communicate results to family members.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29599518      PMCID: PMC6018744          DOI: 10.1038/s41431-017-0057-3

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  27 in total

1.  Short term psychological distress in patients actively approached for genetic counselling after diagnosis of breast cancer.

Authors:  Kathryn J Schlich-Bakker; Carla C Wárlám-Rodenhuis; Jeanne van Echtelt; Jan van den Bout; Margreet G E M Ausems; Herman F J ten Kroode
Journal:  Eur J Cancer       Date:  2006-09-01       Impact factor: 9.162

2.  Genetic epidemiology of BRCA mutations--family history detects less than 50% of the mutation carriers.

Authors:  Pål Møller; Anne Irene Hagen; Jaran Apold; Lovise Maehle; Neal Clark; Bent Fiane; Kjell Løvslett; Eivind Hovig; Anita Vabø
Journal:  Eur J Cancer       Date:  2007-06-15       Impact factor: 9.162

3.  When knowledge of a heritable gene mutation comes out of the blue: treatment-focused genetic testing in women newly diagnosed with breast cancer.

Authors:  B Meiser; V F Quinn; M Gleeson; J Kirk; K M Tucker; B Rahman; C Saunders; K J Watts; M Peate; E Geelhoed; K Barlow-Stewart; M Field; M Harris; Y C Antill; G Mitchell
Journal:  Eur J Hum Genet       Date:  2016-06-22       Impact factor: 4.246

4.  Psychometric properties of the Impact of Event Scale amongst women at increased risk for hereditary breast cancer.

Authors:  B Thewes; B Meiser; I B Hickie
Journal:  Psychooncology       Date:  2001 Nov-Dec       Impact factor: 3.894

5.  A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire.

Authors:  David Cella; Chanita Hughes; Amy Peterman; Chih-Hung Chang; Beth N Peshkin; Marc D Schwartz; Lari Wenzel; Amy Lemke; Alfred C Marcus; Caryn Lerman
Journal:  Health Psychol       Date:  2002-11       Impact factor: 4.267

6.  BRCA1/2 mutation testing in breast cancer patients: a prospective study of the long-term psychological impact of approach during adjuvant radiotherapy.

Authors:  Kathryn J Schlich-Bakker; Margreet G E M Ausems; Maria Schipper; Herman F J Ten Kroode; Carla C Wárlám-Rodenhuis; Jan van den Bout
Journal:  Breast Cancer Res Treat       Date:  2007-08-03       Impact factor: 4.872

7.  Validation of a decision regret scale.

Authors:  Jamie C Brehaut; Annette M O'Connor; Timothy J Wood; Thomas F Hack; Laura Siminoff; Elisa Gordon; Deb Feldman-Stewart
Journal:  Med Decis Making       Date:  2003 Jul-Aug       Impact factor: 2.583

8.  Screening for anxiety and depression in cancer patients: the effects of disease and treatment.

Authors:  T Ibbotson; P Maguire; P Selby; T Priestman; L Wallace
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

9.  Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility.

Authors:  Angela R Bradbury; Linda Patrick-Miller; Jessica Long; Jacquelyn Powers; Jill Stopfer; Andrea Forman; Christina Rybak; Kristin Mattie; Amanda Brandt; Rachelle Chambers; Wendy K Chung; Jane Churpek; Mary B Daly; Laura Digiovanni; Dana Farengo-Clark; Dominique Fetzer; Pamela Ganschow; Generosa Grana; Cassandra Gulden; Michael Hall; Lynne Kohler; Kara Maxwell; Shana Merrill; Susan Montgomery; Rebecca Mueller; Sarah Nielsen; Olufunmilayo Olopade; Kimberly Rainey; Christina Seelaus; Katherine L Nathanson; Susan M Domchek
Journal:  Genet Med       Date:  2014-10-09       Impact factor: 8.822

Review 10.  Cancer genetic risk assessment for individuals at risk of familial breast cancer.

Authors:  Jennifer S Hilgart; Bernadette Coles; Rachel Iredale
Journal:  Cochrane Database Syst Rev       Date:  2012-02-15
View more
  3 in total

1.  Heterogeneity of posttraumatic stress, depression, and fear of cancer recurrence in breast cancer survivors: a latent class analysis.

Authors:  Matteo Malgaroli; Kristin L Szuhany; Gabriella Riley; Carly D Miron; Jae Hyung Park; Jane Rosenthal; Abraham Chachoua; Marleen Meyers; Naomi M Simon
Journal:  J Cancer Surviv       Date:  2022-02-28       Impact factor: 4.442

Review 2.  Hereditary Gastric and Breast Cancer Syndromes Related to CDH1 Germline Mutation: A Multidisciplinary Clinical Review.

Authors:  Giovanni Corso; Giacomo Montagna; Joana Figueiredo; Carlo La Vecchia; Uberto Fumagalli Romario; Maria Sofia Fernandes; Susana Seixas; Franco Roviello; Cristina Trovato; Elena Guerini-Rocco; Nicola Fusco; Gabriella Pravettoni; Serena Petrocchi; Anna Rotili; Giulia Massari; Francesca Magnoni; Francesca De Lorenzi; Manuela Bottoni; Viviana Galimberti; João Miguel Sanches; Mariarosaria Calvello; Raquel Seruca; Bernardo Bonanni
Journal:  Cancers (Basel)       Date:  2020-06-17       Impact factor: 6.639

3.  Psychosocial outcome and health behaviour intent of breast cancer patients with BRCA1/2 and PALB2 pathogenic variants unselected by a priori risk.

Authors:  Heamanthaa Padmanabhan; Nur Tiara Hassan; Siu-Wan Wong; Yong-Quan Lee; Joanna Lim; Siti Norhidayu Hasan; Cheng-Har Yip; Soo-Hwang Teo; Meow-Keong Thong; Nur Aishah Mohd Taib; Sook-Yee Yoon
Journal:  PLoS One       Date:  2022-02-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.